The invention provides application of apoptin combined
peptide to treatment of Alzheimer's
disease. The apoptin combined
peptide used in the invention has the following
amino acid sequences: MetGlyArg, LysLysArg, Arg, GIn, Arg, Arg, LeuLysProProSerLysLysArgleArgleGlyleAlaGlyleThrLeuSerLeuArg, ProArg, Thr, AlaLysArg, ArgleArg, Leu and the like. The apoptin combined
peptide provided by the invention has the following
amino acid sequences: MetGlyArg, LysLysLysArg, Arg, Arg and Leu. Various
animal model experiments prove that after the polypeptide
drug is administered through intravenous injection (with the dosage of 1mg / kg to 3mg / kg),
cognitive impairment,
spatial learning and memory ability of model animals with Alzheimer's
disease, vascular
dementia and
senile dementia can be remarkably improved, and the
treatment effect is superior to that of
donepezil. The action mechanism comprises reduction of
oxidative damage, inhibition of APP and BACE1
pathological protein expression, increase of
neuron number and nissl body content, inhibition of
cell apoptosis and the like. The polypeptide
medicine is high in safety and remarkable in
curative effect, and a new effective
medicine is provided for treating the Alzheimer's
disease.